OPC-415 / Otsuka, Osaka University - LARVOL DELTA

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=11 | Terminated | Sponsor: Otsuka Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Terminated; This is because the decision was made to conclude the trial at Phase I and not proceed to Phase II.

Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=11 | Active, not recruiting | Sponsor: Otsuka Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | N=49 ➔ 11 | Trial primary completion date: Jan 2027 ➔ Apr 2025

Enrollment change • Enrollment closed • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology